Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM19 CAR-T in Refractory or Relapsed B-ALL
NCT03142646Phase 2Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Jun 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IM19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Occurrence of study related adverse events at 2 years. Status: unknown.
02
Drugs
IM19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03142646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142646.